48,868
edits
Line 2: | Line 2: | ||
It is typically positive in TSC1/TSC2/MTOR mutated renal cell carcinomas.<ref name=pmid37661807>{{cite journal |authors=Li H, Argani P, Halper-Stromberg E, Lotan TL, Merino MJ, Reuter VE, Matoso A |title=Positive GPNMB Immunostaining Differentiates Renal Cell Carcinoma With Fibromyomatous Stroma Associated With TSC1/2/MTOR Alterations From Others |journal=Am J Surg Pathol |volume=47 |issue=11 |pages=1267–1273 |date=November 2023 |pmid=37661807 |doi=10.1097/PAS.0000000000002117 |url=}}</ref> | It is typically positive in TSC1/TSC2/MTOR mutated renal cell carcinomas.<ref name=pmid37661807>{{cite journal |authors=Li H, Argani P, Halper-Stromberg E, Lotan TL, Merino MJ, Reuter VE, Matoso A |title=Positive GPNMB Immunostaining Differentiates Renal Cell Carcinoma With Fibromyomatous Stroma Associated With TSC1/2/MTOR Alterations From Others |journal=Am J Surg Pathol |volume=47 |issue=11 |pages=1267–1273 |date=November 2023 |pmid=37661807 |doi=10.1097/PAS.0000000000002117 |url=}}</ref> | ||
==Positive== | ==Positive== | ||
Line 11: | Line 10: | ||
*[[PEComa]]. | *[[PEComa]]. | ||
*[[Renal cell carcinoma with fibromyomatous stroma]]. | *[[Renal cell carcinoma with fibromyomatous stroma]]. | ||
==Negative | |||
*[[Clear cell renal cell carcinoma]]. | |||
*[[Papillary renal cell carcinoma]]. | |||
*[[Chromophobe renal cell carcinoma]]. | |||
*[[Clear cell papillary renal cell tumour]]. | |||
==References== | ==References== |
edits